Preclinical characterization of antiobesity drug MET-097

June 30, 2025

MET-097 is a glucagon-like peptide 1 receptor (GLP-1R) agonist developed at Metsera for treating overweight and obesity and is currently in phase II clinical trials.

BioWorld Science Conferences American Diabetes Association Endocrine/metabolic

Today's news in brief

BioWorld

BioWorld briefs for July 8, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for July 8, 2025.

House passes H.R. 1, restoring R&D tax cuts

BioWorld MedTech

The House of Representatives passed H.R. 1, also known as One Big Beautiful Bill, which will restore personal income tax cuts that expired in 2022. However, the...

Illustration of the β2-adrenergic receptor

Exercise-mimicking compound offers alternative to GLP-1 therapies

BioWorld

An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...

3D rendering of a molecular glue mediating the interaction between two proteins

With surface mimicry, molecular glues shed hairpin need

BioWorld Science

Degradation is a therapeutic strategy that could offer possibilities to get at currently undruggable target proteins. In targeted degradation, compounds induce...